DaVita Inc. (DVA) Presents at 2026 UBS International Healthcare Convention Transcript

Albert Rice
UBS Funding Financial institution, Analysis Division

So we’re 10 months into the 12 months. How has the 12 months been to date? What have been the positives? What have been the surprises, challenges?

Joel Ackerman
CFO & Treasurer

Look, 12 months shouldn’t be over but. Initially, thanks for having us, and howdy, everybody. Yr shouldn’t be over but, however I feel we’ve got a fairly good sense of the contours for the 12 months. I am going to get to the U.S. dialysis enterprise second, however I am going to begin with the opposite 2 companies, worldwide and IKC. Worldwide is simply clicking alongside as anticipated. Nothing stunning there, optimistic or destructive. We have all the time stated over the long-term 1% addition to OI progress, and that is taking place. IKC is having a powerful 12 months. We’re a few 2% contribution to OI progress this 12 months versus the conventional 1% we name out.

And the enterprise, I feel, is simply hitting its stride. We — 5 years in the past, I feel we known as out 2026 was going to be the primary breakeven 12 months, and it is simply continued to click on alongside, rising, delivering nice worth to sufferers and payers, and we’re feeling actually good about that. By way of U.S. dialysis, going into the 12 months, we anticipated it could be a troublesome 12 months. We knew we had challenges on business combine from the ACA. We knew we weren’t going to get again to our regular 2% quantity progress. From — in order that was